Annals of Oncology Advance Access originally published online on September 9, 2007
Annals of Oncology 2007 18(11):1828-1833; doi:10.1093/annonc/mdm332
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2007 European Society for Medical Oncology
urogential tumors |
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients
1 Georges Pompidou European Hospital, Paris
2 Curie Institute, Paris
3 François Baclesse Centre, Caen
4 Antoine-Lacasagne Centre, Nice
5 Cochin Hospital, Paris, France
* Correspondence to: Dr S. Oudard, MD, Georges Pompidou European Hospital, Medical Oncology Department, 20 Leblanc Street, 75015 Paris, France. Tel: +33-1-56-09-34-34; Fax: +33-1-56-09-24-31; E-mail: stephane.oudard{at}egp.aphp.fr
Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival in hormone-refractory prostate cancer (HRPC) patients.
Patients and methods: Data from 250 consecutive metastatic HRPC patients treated with chemotherapy between February 2000 and November 2006 were retrospectively analysed. At least three PSA assays were required within 3 months before chemotherapy. PSA-DT was calculated as ln 2 divided by the slope of the log PSA line, and the difference between two log PSA levels was divided by the time interval. The primary endpoint was overall survival (OS). Survival rates according to PSA-DT were stratified on chemotherapy regimen. Multivariate Cox regression analysis was performed to isolate the impact of PSA-DT on OS, controlling for associate prognostic covariates.
Results: Patients received docetaxel- (82%) or mitoxantrone-based chemotherapy. The median PSA-DT was 45 days (range 4.7–1108 days). There were 174 deaths (70%). The median survival was 16.5 months (95% confidence interval [CI] = 12.5–20.5) and 26.4 months (95% CI = 20.3–32.4) for patients with a PSA-DT < 45 and 
45 days, respectively. In the multivariate setting, the adjusted hazard ratio (HR) was 1.39 (95% CI = 1.03–1.89; P = 0.04), stratified by chemotherapy regimen.
Conclusion: A short PSA-DT before onset of chemotherapy in HRPC patients was associated with an increased risk of death. This could be useful as a stratification parameter in trials with new drugs in a metastatic setting.
Key words: chemotherapy, hormone-refractory prostate cancer, overall survival, predictive factor, prostate-specific antigen doubling time
Received for publication March 26, 2007. Revision received May 15, 2007. Accepted for publication May 21, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. J. Vickers, C. Savage, M. F. O'Brien, and H. Lilja Systematic Review of Pretreatment Prostate-Specific Antigen Velocity and Doubling Time As Predictors for Prostate Cancer J. Clin. Oncol., January 20, 2009; 27(3): 398 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Gravis, F. Bladou, N. Salem, A. Goncalves, B. Esterni, J. Walz, S. Bagattini, M. Marcy, S. Brunelle, and P. Viens Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer Ann. Onc., September 1, 2008; 19(9): 1624 - 1628. [Abstract] [Full Text] [PDF]
|
|